ARPO:NSD-Aerpio Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.00

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

0.17M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Aerpio Pharmaceuticals Inc (ARPO) Stock Analysis:
Based on the Aerpio Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Aerpio Pharmaceuticals Inc is not available over the next 12 months. Aerpio Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aerpio Pharmaceuticals Inc is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Aerpio Pharmaceuticals Inc’s stock price was USD 26.00. Aerpio Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +49.43% over the last year.

About

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of va ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

USD16.75B N/A N/A

ETFs Containing ARPO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 4.42% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.42% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.57% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.57% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 82.18% N/A N/A N/A N/A
Risk Adjusted Return 11.65% N/A N/A N/A N/A
Market Capitalization 0.10B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.98 N/A N/A N/A N/A
Price / Cash Flow Ratio -19.47 N/A N/A N/A N/A
EV/EBITDA 0.24 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.61% N/A N/A N/A N/A
Return on Invested Capital -15.77% N/A N/A N/A N/A
Return on Assets -31.02% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.81 N/A N/A N/A N/A
Short Percent 10.63% N/A N/A N/A N/A
Beta 1.65 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.